Results 211 to 220 of about 6,382,401 (301)

Introduction of a Double‐Headed Nucleotide Into G‐Quadruplex DNA: Position‐Dependent Stabilization and Structural Insights

Chemistry – A European Journal, EarlyView.
A double‐headed bis‐guanine (G) nucleotide (GG) was evaluated as a noncanonical building block in G‐quadruplexes (G4s). Biophysical and computational analyses reveal that GG can directly participate in G‐tetrads and strongly stabilize G4s in a position‐ and topology‐dependent manner. These findings establish design rules for using GG to engineer highly
Krista Urup, Peter Reinholdt, Kasper Munch Beck, Michael Petersen, Jean‐Louis Mergny, Poul Nielsen   +5 more
wiley   +1 more source

Role of cytoreductive nephrectomy in metastatic medullary renal cell carcinoma: controlled analysis. [PDF]

World J Urol
Le QC, Marmiroli A, Longoni M, Falkenbach F, Catanzaro C, Nicolazzini M, Polverino F, Goyal JA, Saad F, Schiavina R, Carmignani LF, Briganti A, Longo N, Graefen M, Palumbo C, Siech C, Banek S, Traumann M, Chun FK, Karakiewicz PI.   +19 more
europepmc   +1 more source

Time‐Dependent Bias and Prognostic Confounding in Exposure–Response Analysis of Targeted Therapies: Lessons from Sunitinib in Metastatic Renal Cancer

Clinical Pharmacology &Therapeutics, EarlyView.
Exposure–response (E–R) analyses of sunitinib in metastatic renal cell carcinoma (mRCC) have supported concentration‐guided dose escalation. However, such analyses may be biased when exposure metrics incorporate post‐baseline dose modifications, time‐varying apparent clearance, or baseline factors that influence both pharmacokinetics and clinical ...
Han Liu, Lena E. Friberg
wiley   +1 more source

Cabozantinib-related pneumothorax in responsive patients with renal cell carcinoma: a case report. [PDF]

J Med Case Rep
Kodaka K, Inakawa T, Kuramochi H.
europepmc   +1 more source

Exposure–Response Analysis of Enfortumab Vedotin Plus Pembrolizumab as First‐Line Therapy for Locally Advanced or Metastatic Urothelial Cancer

Clinical Pharmacology &Therapeutics, EarlyView.
Enfortumab vedotin is a nectin‐4‐directed antibody–drug conjugate currently approved in combination with pembrolizumab for the first‐line treatment of locally advanced or metastatic urothelial cancer. Here we describe the exposure–response relationship between enfortumab vedotin exposures and efficacy/safety endpoints in patients who received ≥1 dose ...
Vaishali L. Chudasama, Helen Kastrissios, Hossam Kadry, Daping Zhang, Salaheldin Hamed, Srinivasu Poondru, Souvik Bhattacharya, Russ Wada, Amit Garg, Yen Lin Chia   +9 more
wiley   +1 more source

Risk Stratification in Renal Cell Carcinoma: A Narrative Review. [PDF]

Cancers (Basel)
Dixon N, Wong V, Bicer F, Dason S, Singer EA.   +4 more
europepmc   +1 more source

Exposure‐Response Analyses of Datopotamab Deruxtecan (Dato‐DXd), a TROP2‐Directed Antibody‐Drug Conjugate, in Advanced Non‐small Cell Lung Cancer

Clinical Pharmacology &Therapeutics, EarlyView.
Exposure‐response analyses supported a favorable benefit‐risk profile of Dato‐DXd at 6 mg/kg Q3W in patients with advanced nonsquamous NSCLC. Datopotamab deruxtecan (Dato‐DXd) is a trophoblast cell‐surface antigen‐2 (TROP2)‐directed antibody‐drug conjugate (ADC) that has demonstrated clinical activity in patients with NSCLC who have received prior ...
Ying Hong, Anna M. Mc Laughlin, Yuzhuo Pan, Sofia Friberg Hietala, Sophie Peigné, Michael Chargualaf, Zoey Tang, Diansong Zhou, Naoyuki Tajima, Malaz Abutarif, Tushar Garimella   +10 more
wiley   +1 more source

Belzutifan-Associated Reversible Heart Failure With Preserved Ejection Fraction in Metastatic Renal Cell Carcinoma. [PDF]

IJU Case Rep
Kimura H, Nakazawa S, Ishizuya Y, Yamamoto Y, Takezawa K, Kato T, Hatano K, Kakuta Y, Kawashima A, Nonomura N.   +9 more
europepmc   +1 more source

Model‐based clinical pharmacology profiling of subcutaneous nivolumab in renal cell carcinoma: Bridging to alternative dosing regimens and indications

Clinical Pharmacology &Therapeutics, EarlyView.
A novel model‐informed drug development (MIDD) approach was employed to derive the coprimary endpoints (time‐averaged serum concentration over 28 days [Cavgd28] and minimum serum concentration at steady state [Cminss]) of the phase III CheckMate 67T study (NCT04810078).
Yue Zhao, Zheyi Hu, Elizabeth Gibson, Li Zhu, Heather Vezina, Anna G. Kondic   +5 more
wiley   +1 more source

Next‐Generation CAR‐T Cell Therapy: From Modular Design to Clinical Expansion

Exploration, EarlyView.
Over the past decades, chimeric antigen receptor (CAR)‐T cell therapy has evolved from a linear engineering concept into a powerful yet constrained immunotherapy, limited by tumour microenvironment barriers, immune evasion, and manufacturing complexity.
Yuesong Bai, Jintao Qin, Zongjun Dai, Ran Yan, Yong Yang, Wenguang Wang   +5 more
wiley   +1 more source